Radiopharmaceuticals

• 

  Subject Areas on Research

  • (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 
  • (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes. 
  • (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 
  • (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. 
  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. 
  • 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. 
  • 18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial. 
  • 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. 
  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • 2-[18F]F-A-85380: a PET radioligand for alpha4beta2 nicotinic acetylcholine receptors. 
  • 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. 
  • 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with low picomolar affinity for alpha4beta2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography. 
  • A 3D model of non-uniform attenuation and detector response for efficient iterative reconstruction in SPECT. 
  • A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT. 
  • A New, Second Generation Trithiol Bifunctional Chelate for 72,77As: Trithiol(b)-(Ser)2-RM2. 
  • A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. 
  • A kit method for the high level synthesis of [211At]MABG. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. 
  • A p-[18F]fluoroethoxyphenyl bicyclic nucleoside analogue as a potential positron emission tomography imaging agent for varicella-zoster virus thymidine kinase gene expression. 
  • A pattern-oriented approach to splenic imaging in infants and children. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). 
  • A programmable smoke delivery device for PET imaging with cigarettes containing 11C-nicotine. 
  • A short-breath-hold technique for lung pO2 mapping with 3He MRI. 
  • A simplified method for the measurement of nonmetabolized 2-[18F]F-A-85380 in blood plasma using solid-phase extraction. 
  • A systematic review of the factors affecting accuracy of SUV measurements. 
  • ACR Appropriateness Criteria Renal Cell Carcinoma Staging. 
  • ACR Appropriateness Criteria Vomiting in Infants up to 3 Months of Age. 
  • ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. 
  • ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. 
  • ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. 
  • ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. 
  • ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. 
  • ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. 
  • ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. 
  • AJR teaching file: incidental breast cancer detected with 18F-FDG PET/CT. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. 
  • Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. 
  • Advances in Lung Cancer Imaging. 
  • Alzheimer disease: operating characteristics of PET--a meta-analysis. 
  • Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography. 
  • American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. 
  • Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 
  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 
  • An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. 
  • An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy. 
  • An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. 
  • An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. 
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 
  • Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. 
  • Antiseptic-Mediated Colloid Labeling as a Potential Source of Abnormal Liver and Spleen Uptake with 99mTc-Dimercaptosuccinic Acid. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. 
  • Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. 
  • Association of bone scintigraphic abnormalities with knee malalignment and pain. 
  • Associations between dopamine D2 receptor availability and BMI depend on age. 
  • Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. 
  • Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. 
  • Astatine-211: production and availability. 
  • Attenuation correction in hybrid positron emission tomography. 
  • Automated radiochemical synthesis and biodistribution of [¹¹C]l-α-acetylmethadol ([¹¹C]LAAM). 
  • Automated radiosynthesis of [11C]morphine for clinical investigation. 
  • Bariatric Radioembolization: A Pilot Study on Technical Feasibility and Safety in a Porcine Model. 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. 
  • Brain FDG PET and the diagnosis of dementia. 
  • Brain PET in the diagnosis of Alzheimer's disease. 
  • Breast tumour imaging using incomplete circular orbit pinhole SPET: a phantom study. 
  • Cardiopulmonary bypass time does not affect cerebral blood flow. 
  • Cardiovascular Imaging With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Fibroinflammatory Disorders. 
  • Cardiovascular disease risk stratification with stress single-photon emission computed tomography technetium-99m tetrofosmin imaging in patients with the metabolic syndrome and diabetes mellitus. 
  • Case 260: Endobronchial Posttransplantation Lymphoproliferative Disease. 
  • Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. 
  • Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. 
  • Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 
  • Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. 
  • Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow. 
  • Chemistry and radiochemistry of As, Re and Rh isotopes relevant to radiopharmaceutical applications: high specific activity radionuclides for imaging and treatment. 
  • Chronic CSF leak into the peritoneal cavity shown by radionuclide cisternography. Successful treatment with an epidural blood patch. 
  • Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study. 
  • Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients. 
  • Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. 
  • Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. 
  • Clinical and Technical Considerations for Brain PET Imaging for Dementia. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Clinical oncologic positron emission tomography: an introduction. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinical results of a novel wide beam reconstruction method for shortening scan time of Tc-99m cardiac SPECT perfusion studies. 
  • Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. 
  • Colonic uptake of Tc-99m MDP in pseudomembranous colitis. 
  • Combined Tc-99m sestamibi first-pass radionuclide angiography and cardiac SPECT imaging during arbutamine infusion delivered by a computerized closed-loop system. 
  • Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. 
  • Comparison of Tc99m-DTPA and indium-111 DTPA studies of baclofen pump function. 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Complementary nature of radiotracer parathyroid imaging and intraoperative parathyroid hormone assays in the surgical management of primary hyperparathyroid disease: case report and review. 
  • Comprehensive nutrient consumption estimation and metabolic profiling during ketogenic diet and relationship with myocardial glucose uptake on FDG-PET. 
  • Computed high b-value diffusion-weighted imaging improves lesion contrast and conspicuity in prostate cancer. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. 
  • Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. 
  • Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: implementation and validation. 
  • Correction of hysteretic respiratory motion in SPECT myocardial perfusion imaging: Simulation and patient studies. 
  • Correlation between changes in regional cerebral blood flow and pain relief in complex regional pain syndrome type 1. 
  • Correlation of CT Angiography and 99mTechnetium-Labeled Red Blood Cell Scintigraphy to Catheter Angiography for Lower Gastrointestinal Bleeding: A Single-Institution Experience. 
  • Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. 
  • Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. 
  • Current status of therapy of solid tumors: brain tumor therapy. 
  • Decreased cerebrospinal fluid absorption during abdominal insufflation. 
  • Deep Learning-Based Computed Tomography Perfusion Mapping (DL-CTPM) for Pulmonary CT-to-Perfusion Translation. 
  • Definitive diagnosis of cerebrospinal fluid leak into the pleural space using 111In-DTPA cisternography. 
  • Detecting pheochromocytoma: defining the most sensitive test. 
  • Detection of a large substernal goiter during Tc-99m tetrofosmin cardiac SPECT imaging. 
  • Detection of early changes in renal function using 99mTc-MAG3 imaging in a murine model of ischemia-reperfusion injury. 
  • Development of Novel ¹⁸ F-PET Agents for Tumor Hypoxia Imaging. 
  • Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. 
  • Diagnosis of pancreatic carcinoma: role of FDG PET. 
  • Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. 
  • Diffusion-weighted hyperpolarized 129Xe MRI in healthy volunteers and subjects with chronic obstructive pulmonary disease. 
  • Direct measurement of lung motion using hyperpolarized helium-3 MR tagging. 
  • Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
  • Dithiol Aryl Arsenic Compounds as Potential Diagnostic and Therapeutic Radiopharmaceuticals. 
  • Dopamine-modulated aversive emotion processing fails in alcohol-dependent patients. 
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
  • Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. 
  • Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. 
  • Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. 
  • Echocardiography for the assessment of myocardial viability. 
  • Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection. 
  • Effect of Immunosuppressive Therapy and Biopsy Status in Monitoring Therapy Response in Suspected Cardiac Sarcoidosis. 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Efficiency comparison between 99m Tc-tetrofosmin and 99m Tc-sestamibi myocardial perfusion studies. 
  • Emerging role of positron emission tomography (PET) imaging in cardiac surgery. 
  • Enabling hyperpolarized (129) Xe MR spectroscopy and imaging of pulmonary gas transfer to the red blood cells in transgenic mice expressing human hemoglobin. 
  • Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. 
  • Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 
  • Evaluation of 72Se/72As generator and production of 72Se for supplying 72As as a potential PET imaging radionuclide. 
  • Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers. 
  • Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. 
  • Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. 
  • Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET. 
  • Evaluation of primary pulmonary carcinoid tumors using FDG PET. 
  • Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. 
  • Evolving role of FDG PET/CT in multiple myeloma imaging and management. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. 
  • FDG PET imaging in patients with pathologically verified dementia. 
  • FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. 
  • FDG PET of pleural effusions in patients with non-small cell lung cancer. 
  • FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. 
  • FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. 
  • FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 
  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. 
  • FDG PET/CT in patients with HIV. 
  • FDG PET/CT in the management of colorectal and anal cancers. 
  • FDG PET/CT in the management of nasopharyngeal carcinoma. 
  • FDG PET/CT in the management of primary pleural tumors and pleural metastases. 
  • FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. 
  • FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. 
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. 
  • FDG-PET finding in early-phase Takayasu arteritis. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. 
  • FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. 
  • FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. 
  • FDG-PET/CT characterization of adrenal nodules: diagnostic accuracy and interreader agreement using quantitative and qualitative methods. 
  • FTO affects food cravings and interacts with age to influence age-related decline in food cravings. 
  • Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. 
  • False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. 
  • Fibrogenesis imperfecta ossium: MR imaging of the axial and appendicular skeleton and correlation with a unique radiographic appearance. 
  • First-pass radionuclide angiography. 
  • Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 
  • Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. 
  • Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management. 
  • Fortuitous detection of papillary carcinoma of the thyroid with F-18 FDG positron emission tomography in a patient with non-Hodgkin lymphoma. 
  • Fractal texture analysis of perfusion lung scans. 
  • Gangliogliomas: characterization by registered positron emission tomography-MR images. 
  • Gastrointestinal bleeding in adult patients with Meckel's diverticulum: the role of technetium 99m pertechnetate scan. 
  • Gated 99mTc-tetrofosmin and 18F-FDG studies: a comparison of single-acquisition and separate-acquisition protocols. 
  • Gating provides improved accuracy for differentiating artifacts from true lesions in equivocal fixed defects on technetium 99m tetrofosmin perfusion SPECT. 
  • Gender Differences in Radiation Dose From Nuclear Cardiology Studies Across the World: Findings From the INCAPS Registry. 
  • Gender-specific vulnerability for rCBF abnormalities among cocaine abusers. 
  • Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. 
  • Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. 
  • Head and Neck Cancer and PET/Computed Tomography. 
  • Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. 
  • Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Hibernoma: 18F FDG PET/CT imaging. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent. 
  • Human ovarian cancers express somatostatin receptors. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. 
  • IV Contrast Material for PET/CT: Point-Putting the CT Into PET/CT. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Imaging biomarker roadmap for cancer studies. 
  • Imaging drug resistance with radiolabeled molecules. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. 
  • Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. 
  • Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions. 
  • Impact of Point-Spread Function Reconstruction on 68Ga-DOTATATE PET/CT Quantitative Imaging Parameters. 
  • Impact of short access nicotine self-administration on expression of α4β2* nicotinic acetylcholine receptors in non-human primates. 
  • Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. 
  • Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. 
  • Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT. 
  • Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. 
  • In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. 
  • Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: a comparison with clinical and perfusion variables. 
  • Individual differences in dopamine D2 receptor availability correlate with reward valuation. 
  • Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in head and neck melanoma. 
  • Interesting image. F-18 fluorodeoxyglocose positron emission tomography/computed tomography in the diagnosis of chronic myopathic sarcoidosis. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. 
  • Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). 
  • Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 
  • Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. 
  • Intraoperative probes and imaging probes. 
  • Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. 
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. 
  • Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. 
  • Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. 
  • Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? 
  • Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 
  • Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. 
  • JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. 
  • Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. 
  • Kaposi sarcoma after bilateral lung transplantation. 
  • Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. 
  • Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. 
  • Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. 
  • Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography. 
  • Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment. 
  • Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. 
  • Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. 
  • Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. 
  • Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice. 
  • Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. 
  • Lung cancer and positron emission tomography with fluorodeoxyglucose. 
  • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. 
  • MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. 
  • MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 
  • Magnetic resonance versus radionuclide pharmacological stress perfusion imaging for flow-limiting stenoses of varying severity. 
  • Magnitude of abdominal incision affects the duration of postoperative ileus in rats. 
  • Mammotomography with pinhole incomplete circular orbit SPECT. 
  • Management of advanced neuroendocrine tumors with hepatic metastasis. 
  • Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. 
  • Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. 
  • Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. 
  • Mechanistic Insights into Sympathetic Neuronal Regeneration: Multitracer Molecular Imaging of Catecholamine Handling After Cardiac Transplantation. 
  • Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. 
  • Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. 
  • Metastatic melanoma to the heart. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology. 
  • Molecular Imaging and Therapy for Neuroendocrine Tumors. 
  • Molecular Imaging in the Head and Neck: Diagnosis and Therapy. 
  • Molecular imaging of hypoxia. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. 
  • Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images. 
  • N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules. 
  • N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. 
  • N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. 
  • N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. 
  • NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. 
  • Net endogenous acid production is associated with a faster decline in GFR in African Americans. 
  • New and emerging therapies for bone metastases in genitourinary cancers. 
  • New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps? 
  • No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. 
  • No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. 
  • Non-ST-segment elevation acute coronary syndromes: targeted imaging to refine upstream risk stratification. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. 
  • O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). 
  • Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. 
  • PET Imaging for Head and Neck Cancers. 
  • PET Imaging of Oral Cavity and Oropharyngeal Cancers. 
  • PET and brain tumor image fusion. 
  • PET imaging in patients with bronchioloalveolar cell carcinoma. 
  • PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. 
  • PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors. 
  • PET/CT of Dementia. 
  • PET/CT of cancer patients: part 1, pancreatic neoplasms. 
  • PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 
  • PET/Computed Tomography and Precision Medicine: Gastric Cancer. 
  • PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma. 
  • PET/Computed Tomography: Laryngeal and Hypopharyngeal Cancers. 
  • PET/Computed Tomography: Post-therapy Follow-up in Head and Neck Cancer. 
  • Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. 
  • Parathyroid 4D CT and Scintigraphy: What Factors Contribute to Missed Parathyroid Lesions? 
  • Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. 
  • Patient and tumor characteristics predictive of an elevated hepatopulmonary shunt fraction before radioembolization of hepatic tumors. 
  • Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane. 
  • Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). 
  • Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. 
  • Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism. 
  • Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. 
  • Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. 
  • Positron emission tomography detection of metastatic penile squamous cell carcinoma. 
  • Positron emission tomography imaging of brain tumors. 
  • Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. 
  • Positron emission tomography: brain tumors and lung cancer. 
  • Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol. 
  • Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. 
  • Precision Medicine and PET-Computed Tomography in Pediatric Malignancies. 
  • Precision Medicine and PET/Computed Tomography in Melanoma. 
  • Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma. 
  • Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. 
  • Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. 
  • Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. 
  • Prediction of mortality in patients with coronary artery disease undergoing vasodilator stress testing: a comparison between 99mTc-tetrofosmin and 99mTc-sestamibi. 
  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. 
  • Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction. 
  • Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis. 
  • Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. 
  • Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. 
  • Pulmonary function, bronchial reactivity, and epithelial permeability are response phenotypes to ozone and develop differentially in healthy humans. 
  • Quantification of myocardial hypoperfusion with 99m Tc-sestamibi in patients undergoing prolonged coronary artery balloon occlusion. 
  • Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. 
  • Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. 
  • Quantitative regional wall motion analysis with early contrast ventriculography for the assessment of myocardium at risk in acute myocardial infarction. 
  • Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. 
  • Radioimmunotherapy with alpha-particle emitting radionuclides. 
  • Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles. 
  • Radiosynthesis of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-[(11)C]methyl-2-(S)-pyrrolidinylmethoxy)pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. 
  • Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. 
  • Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. 
  • Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. 
  • Receiver operating characteristic evaluation of iterative reconstruction with attenuation correction in 99mTc-sestamibi myocardial SPECT images. 
  • Recommendations on the use of 18F-FDG PET in oncology. 
  • Reduced effects of age on dopamine D2 receptor levels in physically active adults. 
  • Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. 
  • Registration of three-dimensional magnetic resonance and radionuclide skeletal images. 
  • Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. 
  • Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. 
  • Retrodisplaced gallbladder detected on hepatobiliary scintigraphy. 
  • Risk assessment and economic impact analysis of the implementation of new European legislation on radiopharmaceuticals in Italy: the case of the new monograph chapter Compounding of Radiopharmaceuticals (PHARMEUROPA, Vol. 23, No. 4, October 2011). 
  • Role of Non-FDG-PET/CT in Head and Neck Cancer. 
  • SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. 
  • Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. 
  • Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. 
  • Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. 
  • Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. 
  • Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. 
  • Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. 
  • Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. 
  • Synthesis and biological evaluation of an 123I-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. 
  • Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. 
  • Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. 
  • Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. 
  • Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. 
  • Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. 
  • Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. 
  • Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues. 
  • Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor. 
  • T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. 
  • Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland. 
  • Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. 
  • Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. 
  • The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. 
  • The cumulative radiation dose paradigm in pediatric imaging. 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. 
  • The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism. 
  • The influence of mechanical compression on the induction of osteoarthritis-related biomarkers in articular cartilage explants. 
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. 
  • The progress and promise of molecular imaging probes in oncologic drug development. 
  • The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. 
  • The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. 
  • The role of PET scanning in the detection of recurrent cervical cancer. 
  • The role of PET/CT in the management of cervical cancer. 
  • The use of positron emission tomography in cerebrovascular disease. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. 
  • The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. 
  • The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma. 
  • Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. 
  • Thoracic FDG PET: state of the art. 
  • Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. 
  • Transcranial Doppler blood flow velocity versus 133Xe clearance cerebral blood flow during mild hypothermic cardiopulmonary bypass. 
  • Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. 
  • Transmission scanning system for a gamma camera coincidence scanner. 
  • Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals. 
  • Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. 
  • Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. 
  • Two-time-point FDG PET/CT: liver SULmean repeatability. 
  • Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer. 
  • Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. 
  • Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review. 
  • Use of florbetapir-PET for imaging beta-amyloid pathology. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Utility of FDG PET/CT in inflammatory cardiovascular disease. 
  • Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. 
  • Utilization of Indocyanine Green to Aid in Identifying Sentinel Lymph Nodes in Merkel Cell Cancer. 
  • Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. 
  • Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. 
  • Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. 
  • Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. 
  • Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer. 
  • Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. 
  • Value of PET/CT in the management of liver metastases, part 1. 
  • Value of PET/CT in the management of primary hepatobiliary tumors, part 2. 
  • Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. 
  • Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. 
  • Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • [(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. 
  • [18F]Fluoro-L-dopa PET/CT in congenital hyperinsulinism. 
  • d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Driehuys, Bastiaan, Professor of Radiology, Biomedical Engineering
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology